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 B-13/H cells are null for functional
SULT1A1 but express functional
SULT2B1 activity.
 B-13/H cells activate 10 hydroxyes-
tragole to a genotoxic metabolite.
 SULT2B1 is expressed in cholangio-
cytes in rat and human liver.
 B-13/H cells express a cholangiocyte
pattern of sulphotransferase (SULT)
expression.
 Tumours in estragole-exposed rats
may be dependent on cholangiocyte
SULT2B1.
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A B S T R A C T
Rat B-13 progenitor cells are readily converted into functional hepatocyte-like B-13/H cells capable of
phase I cytochrome P450-dependent activation of pro-carcinogens and induction of DNA damage. The
aim of the present study was to investigate whether the cells are also capable of Phase II
sulphotransferase (SULT)-dependent activation of a pro-carcinogen to an ultimate carcinogen. To this
end we therefore examined the bioactivation of the model hepatic (hepato- and cholangio-) carcinogen
estragole and its proximate SULT1A1-activated genotoxic metabolite 10-hydroxyestragole. Exposing B-
13 or B-13/H cells to estragole (at concentrations up to 1 mM) resulted in the production of low levels of
10-hydroxyestragole, but did not result in detectable DNA damage. Exposing B-13/H cells – but not B-13
cells – to 10-hydroxyestragole resulted in a dose-dependent increase in DNA damage in comet assays,
confirmed by detection of N2-(trans-isoestragol-30-yl)-20-deoxyguanosine adducts. Genotoxicity was
inhibited by general SULT inhibitors, supporting a role for SULTS in the activation of 1-hydroxyestragole
in B-13/H cells. However, B-13 and B-13/H cells did not express biologically significant levels of SULT1A1
as determined by qRT-PCR, Western blotting and its associated 7-hydroxycoumarin sulphation activity.
B-13 and B-13/H cells expressed – relative to intact rat liver – high levels of SULT2B1 (primarily the
b isoform) and SULT4A1 mRNAs and proteins. B-13 and B-13/H cells also expressed the
Abbreviations: CYP, cytochrome P450s; DEX, dexamethasone; E-30-N2-dGuo, N2-(trans-isoestragol-30-yl)-20-deoxyguanosine; GSTs, glutathione S transferases; OTM, olive
tail moment; PAPSS, 30-phosphoadenosine 50-phosphosulphate synthase; PCP, pentachlorophenol; PNP, r-nitrophenol; SULT, sulphotransferase; UDPGTs, UDP-glucuronyl
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cofactor 30-phosphoadenosine 50-phosphosulphate. However, only B-13/H cells expressed functional
SULT activities towards SULT2B1 substrates DHEA, pregnenolone and 4 methylumbelliferone. Since liver
progenitor cells are bi-potential and also form cholangiocytes, we therefore hypothesised that B-13 cells
express a cholangiocyte-like SULT profile. To test this hypothesis, the expression of SULTs was examined
in liver by RT-PCR and immunohistochemistry. SULT2B1 – but not SULT1A1 – was determined to be
expressed in both rat and human cholangiocytes. Since 10-hydroxyestragole exposure readily produced
DNA injury in B-13/H cells, these data suggest that cholangiocarcinomas generated in rats fed estragole
may be dependent, in part, on SULT2B1 activation of the 10-hydroxyestragole metabolite.
ã 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Genotoxicity refers to the process by which chemicals or other
agents damage DNA, leading to an alteration in DNA structure,
information content or segregation (EFSA, 2011). In the absence of
effective repair, genotoxicity is the first step in the initiation of
mutagenesis and potentially of carcinogenesis (EFSA, 2011). For
drugs and chemicals therefore, knowledge of any potential
genotoxic activity is essential in any assessment of safety.
A variety of in vitro assays have been developed to screen for
potential genotoxic chemicals. Since chemicals are very often
indirect genotoxins and require metabolism to display their
genotoxic activity, many assays (e.g. Ames tests, micronucleus
tests) include the option of addition of liver extracts rich in
enzymes that activate indirect genotoxins (e.g. S9 extracts).
Hepatocytes provide an opportunity to examine potential chemical
genotoxicity in cells that express a complex complement of
xenobiotic metabolising enzymes (activating and de-activating) in
an intact cell-based model. However, human hepatocytes are in
short supply (and are of variable quality) and hepatocytes from
animals require donors. Primary hepatocytes also rapidly de-
differentiate in culture (Wallace et al., 2010a).
This group has therefore investigated the utility of a male rat
progenitor B-13 cell as a cost-effective donor-free hepatocyte
source and model system to screen for both chemical toxicity and
genotoxicity (Marek et al., 2003; Wallace et al., 2010a; Probert
et al., 2014a; Fairhall et al., 2013). The B-13 cell line is readily
expandable on simple plastic and basic culture media and in
response to a single glucocorticoid hormone treatment, trans-
differentiates into a non-replicative hepatocyte-like (B-13/H) cell
expressing near normal levels of many cytochrome P450 (CYP)
enzymes in a masculine pattern (Marek et al., 2003; Wallace et al.,
2010b; Probert et al., 2015). The CYPs are functional, metabolise
probe substrates and activate CYP-activated hepatotoxins (Marek
et al., 2003; Wallace et al., 2010b; Fairhall et al., 2013).
Furthermore, the majority of the CYP induction pathways appear
to be intact and in the B-13/H phenotype, induction and metabolic
activation of several genotoxins (benz[a]pyrene, PhIP, aflatoxin B1)
has been demonstrated (Probert et al., 2014a). In contrast to
primary hepatocytes, B-13/H cells also remain differentiated on
plastic for several weeks (Marek et al., 2003). The B-13 cell system
therefore offers a potential model system in which to study
chemical toxicity and genotoxicity. The added value of this system
is that animal donors are not required, it is relatively easy to
generate genetically-modified variants of the cell line (e.g.
modulate expression of genes predicted to impact on toxicity/
genotoxicity) and production of large quantities of cells is cost
effective when compared to less functional stem cell-derived
hepatocytes (Probert et al., 2015).
Since some genotoxins require phase II enzyme systems for
activation to a proximate genotoxin, the B-13 platform was
therefore examined for its ability to identify a genotoxin requiring
phase II activation. Estragole is an alkenylbenzene (for structuresee Fig. 1A) naturally present in herbs such as tarragon, basil and
fennel (EU-SCF, 2001). Estragole is extensively metabolised to non-
toxic metabolites (Alhusainy et al., 2012). However, monoxyge-
nation at the 10 position to produce 10-hydroxyestragole by
predominantly CYP1A2 and CYP2A6 in man (Jeurissen et al.,
2007), followed by conjugation with sulphate by suphotransfer-
ases (SULTs) leads to the generation of 10-sulphoxyestragole, which
is unstable and forms a reactive carbocation (Phillips et al., 1981;
Gardner et al., 1996; Jeurissen et al., 2007). Estragole has been
shown to cause multiple cholangiocarcinomas and hepatocellular
adenoma in the liver of male rats (Miller et al., 1983; Bristol, 2011)
with reactive metabolite formation in the liver recently confirmed
(Ding et al., 2015).
A screen for phase II enzymes in B-13 cells indicated that there
is an up-regulation in the expression of these genes in B-13/H
(compared with B-13 cells) and that B-13/H cells expressed 5 (from
a total of 14) SULTs, 5 (from a total of 8 hepatic) UDP-glucuronyl
transferases and 15 (from a total of 21) glutathione S transferases
transcripts (Probert et al., 2014a). We therefore hypothesised that
B-13/H cells are capable of SULT-mediated sulphation and
therefore of activating chemicals that require sulphation for
genotoxicity.
In this paper, we examine the activation of estragole and 10-
hydroxyestragole in the B-13 and B-13/H cells; examine the effect
of SULT inhibitors on genotoxicity and screen for the presence of
N2-(trans-isoestragol-30-yl)-20-deoxyguanosine (E-30-N2-dGuo)
adducts. We demonstrate for the first time that B-13/H cells
express functional SULT2B1 activity and that hepatocytes and
cholangiocytes express this isoform in both rat and human liver.
2. Materials and methods
2.1. Isolation of cholangiocytes
Rat liver cholangiocytes were isolated essentially as a mixed
population with fibroblasts and a minor progenitor component cell
population by pronase digestion of the biliary tree remaining after
a two-step collagenase digestion of rat liver, see Probert et al.
(2015). A relatively pure population of human liver cholangiocytes
were isolated using an immune-bead approach (which is not
suitable for rat cholangiocytes). In brief, liver (typically 1–2 cm2)
was diced (1–2 mm2) in a sterile Petri dish using a sterile scalpel
blade and then transferred to 5 ml of 10 mg/ml collagenase A and
2 ml of 2 mg/ml DNase I. The volume was made up to 50 ml with
pre-warmed 1x PBS (137 mM NaCl, 2.7 mM KCl, 10 mM phosphate
pH 7.4) and incubated at 37 C for 30–45 min. The digest was then
filtered through Nybolt mesh and centrifuged at 600  g for 5 min.
The supernatant was discarded and the cell pellets were re-
suspended in 1x PBS and centrifugation repeated twice with a
small amount of DNase I added at each re-suspension. Chol-
angiocytes were initially semi-purified using density gradient
centrifugation. Percoll (GE Healthcare) was diluted 9:1 (v/v) with
10x PBS (1.37 M NaCl, 27 mM KCl, 100 mM phosphate pH 7.4). This
Fig. 1. 10-hydroxyestragole but not estragole caused dose-dependent DNA damage in B-13/H cells. A. Structure of estragole. Arrow indicates site of cytochrome-mediated 10
hydroxylation. B. Fluorescent photomicrograph of B-13 and B-13/H cell DNA following 10-hydroxyestragole treatment and comet assay. DNA was stained with SYBR gold and
visualised using the FITC filter. C. DNA damage in B-13 and B-13/H cells treated as indicated after 24 h. *indicates significantly different. D. DNA damage in B-13/H cells treated
with different concentrations of 1'-hydroxyestragole for 24 h. *indicates significantly different to vehicle treated cells.
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3 ml of stock diluted 1:0.3 (v/v) with 1x PBS in a 13 ml sterile falcon
tube. Three ml of cells suspension was then layered onto the top of
each percoll layer followed by centrifugation at 670  g for 30 min
at 80% acceleration and 0% deceleration in a swing out rotor. The
lower percoll/percoll interface was enriched in cholangiocytes and
these were collected, added to 3 volumes of 1x PBS, pelleted by
centrifugation at 600  g for 5 min and re-suspended in 9 ml of 0.1%
BSA in 1x PBS. This suspension was then subjected to immuno-
magnetic purification using HEA-125 Dynabeads (Thermofisher,
UK) essentially according to the manufacturer’s instructions. Cells
were normally used directly for analysis, however a proportion of
cells were routinely cultured in 1:1 [v/v] DMEM:Hams F12 medium
supplemented with 10% (v/v) FBS, 2 mM glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin, 10 ng/ml epidermal growth
factor (EGF), 0.248 IU/ml Insulin, 2 mg/ml hydrocortisone, 10 ng/ml
cholera toxin, 2 nM tri-iodo-L-thyronine and 5 ng/ml hepatocyte
growth factor (HGF) to assess purity. Human liver tissue was
prepared from the margins of tissue removed from patients having
a resection for both benign and malignant tumours. Tissue wasobtained with patient consent and with approval of the Newcastle
& North Tyneside 2 Research Ethics Committee.
2.2. Cell culture
B-13 cells were routinely cultured in low glucose (1 g/L)
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% (v/
v) fetal calf serum (FCS), 100 units/ml penicillin, 100 mg/ml
streptomycin and 0.584 g/L L-glutamine at 37 C in an humidified
incubator gassed with 5% CO2 in air. B-13 cells were sub-cultured
every 2–3 days by trypsinization or differentiated to B-13/H cells
via treatment with 10 nM dexamethasone (DEX) for 14 days, with
media changes every 2–3 days.
2.3. Comet assay
Genotoxicity, expressed as the mean olive tail moment (OTM),
was calculated from 50 individual cells using Autocomet software
(Tritek Corp., Summerduck, Virginia) essentially as previously
outlined (Probert et al., 2014a). Cells were pre-treated with
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hydroxyestragole for 24 h and analysis. To control for any effects on
cell viability and proliferation (which can give false positive
results), compounds were separately tested for cytotoxicity or DNA
synthesis as described (Mosesso et al., 2012; Probert et al., 2014a).
2.4. DNA adducts
Cells were pre-treated with potential inhibitors for 6 h prior to
exposure to estragole or 10-hydroxyestragole for 24 h. Cells were
then scraped into ice-cooled PBS (137 mM NaCl, 2.7 mM KCl,10 mM
phosphate pH 7.4), centrifuged at 16,000  g for 60 s and snap
frozen in liquid nitrogen. DNA was purified from the cell pellets
using a Get pure DNA Kit-Cell protocol (Dojindo Molecular
Technology Inc., Kumamoto, Japan) following the manufacturer’s
instructions for tissue. The DNA was re-suspended in 100 mL MilliQ
water and the yield and purity determined by measuring the
absorbance ratio at 260 nm and 280 nm using a molar extinction
coefficient for double stranded DNA of 50 (L/mol/cm). DNA
samples with an absorbance ratio of 1.8–2.0 were considered
sufficiently pure. Digestion of DNA, and quantification of E-30-N2-Table 1
DNA oligonucleotide sequences employed in qRT-PCR and RT-PCR.
Oligo ID 5'-3' sequence Comments
qRT-PCR
rSULT1A1US ACACATCTGCCCCTGTCCT Will amplify 77 bp cDNA fragm
rSULT1A1DS GCATTTCGGGCAATGTAGA
rSULT1B1US CGAGATGTTATTACCTCTAAAGTTCCA Will amplify 88 bp cDNA fragm
rSULT1B1DS GAGTTTTCTTCAAGAGTTCAACACC
rSULT2B1US CCCACCTCCCTATTGAACTG Will amplify 70 bp cDNA fragm
rSULT2B1DS CGGCCCAAGTAAATCACCT
rSULT4A1US AAGATATGCACCGGGACCT Will amplify 65 bp cDNA fragm
rSULT4A1DS ACAGGACACACCCAGGAATC
rPAPSS1US TTGCAGTGCCTTCATTTTGA Will amplify 60 bp cDNA fragm
rPAPSS1DS AGGCACGGATAAGTTGATGAC
rPAPSS2US ACCCTACTGGACGATGGAGT Will amplify 119 bp cDNA frag
rPAPSS2DS CTCCGGCCTTCGTACATCAA
r18SrRNAUS CCCGAAGCGTTTACTTTGAA Will amplify 136 bp cDNA frag
r18SrRNADS CCCTCTTAATCATGGCCTCA
–
RT-PCR
rSULT2B1aUS TCACTGGAGAAACTGAGGCAGG Will amplify 319 bp cDNA frag
rSULT2B1aDS GGAAGGCTGAAGGCACTTATGG
rSULT2B1bUS ATGGGGCTCATTGGAGAACAG Will amplify 307 bp cDNA frag
rSULT2B1bDS TGGAAGGCTGAAGGCACTTATG
rALBUMINUS TGGTCGCAGCTGTCCGTCAGA Will amplify 192 bp cDNA frag
rALBUMINDS CAGGTCGCCGTGACAGCACTC
rCK-19US TTGGGTCAGGGGGTGTTTTC Will amplify 446 bp cDNA frag
rCK-19DS CTCAAACTTGGTCCGGAAGTC
hSULT1A1US AGCTCAGAGAACAACCCTGC Will amplify 92 bp cDNA fragm
hSULT1A1DS CTGAGCTCTTGGGAACCTGG
hSULT1B1US TATGCGTAAAGGGACGGCTG Will amplify 115 bp cDNA frag
hSULT1B1DS TGTGCGGAATTGAAGTGCAG
hSULT2B1aUS TCCCTACTCTCCCTCATGGC Will amplify 197 bp cDNA frag
hSULT2B1aDS ATCCAGGTCGTGCCTGACT
hSULT2B1bUS GGGCTTGTGGGACACCTATG Will amplify 198 bp cDNA frag
hSULT2B1bDS ATCCAGGTCGTGCCTGACT
hSULT4A1US GGTGGTCTACTTGGTGAGCC Will amplify 128 bp cDNA frag
hSULT4A1DS GGGGAGAGGTCAGTTCCTTG
hPAPSS1US GCAGAACTGGGGAATGCAGAG Will amplify 164 bp cDNA frag
hPAPSS1DS AGGCCATGCTCACAGTAGTC
hPAPSS2US GACACCCTGCTAGATGATGG Will amplify 115 bp cDNA frag
hPAPSS2DS CACCATGTGCCAGGACAAAC
hALBUMINUS AGCTGCCTGTCTGTTGCCAAA Will amplify 134 bp cDNA frag
hALBUMINDS AGGCGAGCTACTGCCCATGC
hCK-19US CAGCTTCTGAGACCAGGGTT Will amplify 725 bp cDNA frag
hCK-19DS GCCCCTCAGCGTACTGATTT
rmhGAPDHUS TGACATCAAGAAGGTGGTGAAG Will amplify 243 bp rat (NM_01
dehydrogenase (Wallace et al.,rmhGAPDHDS2 TCTTACTCCTTGGAGGCCATGTdGuo was performed as previously described using LC/MS-MS
(Paini et al., 2010).
2.5. mRNA analysis
Total RNA was isolated from cultured cells or rat tissues (male
adult Sprague-Dawley) using TRIzol (Invitrogen, Paisley, UK)
following the manufacturer’s instructions. SYBR green was used
for quantitative RT-PCR using a 7500 Fast Applied Biosciences
thermocycler essentially as previously outlined (Probert et al.,
2014a). The primer sequences are given in Table 1 and single
amplicons determined by ethidium bromide agarose gel electro-
phoresis as previously outlined (Leel et al., 2004).
2.6. Western blotting
Western blotting was performed essentially as previously
described (Marek et al., 2005). The antibodies used in these
studies were rabbit anti-SULT1A1 (av49134, Sigma Chemical Co.,
Poole, UK), rabbit anti-SULT1B1 (ab89707, Abcam, Cambridge, UK),
goat anti-SULT2B1 (sc-46542, Santa Cruz, Heidelberg, Germany),ent of NM_031834.1 (Probert et al., 2014a).
ent of NM_022513.2 (Probert et al., 2014a).
ent of NM_001039665.1.
ent of NM_031641.1.
ent of NM_001106471.1.
ment of NM_001106375.2.
ment of NR_046237.1 (Probert et al., 2014a)
ment of NM_001039665.1 (Kohjitani et al., 2006).
ment of XM_006229031.2 (Kohjitani et al., 2006).
ment of NM_134326.2
ment of NM_199498.2
ent of NM_001055.3
ment of NM_014465.3
ment of NM_004605.2 also refered to as transcript variant 1
ment of NM_177973.1 also referred to as transcript variant 2
ment of NM_014351.3
ment of NM_005443.4
ment of NM_004670.3
ment of NM_000477.5
ment of NM_002276.4
7008), human (NM_002046) or mouse (NM_008084) glyceraldehyde 3 phosphate
 2010b).
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(ab155600, Abcam) and rabbit anti-PAPSS2 (ab155588, Abcam).
The anti-SULT2B1 antibody is reported by the manufacturer to
cross-react with both rat and human SULT2A1a and SULT2A1b
isoforms. Detection was carried out using the relevant anti-IgG
horseradish peroxidase (HRP)—conjugated secondary antibody
and ECL-based chemiluminescent detection (GE Healthcare,
Amersham, UK).Fig. 2. 10-hydroxyestragole but not estragole caused SULT-dependent DNA damage in B-
inhibitors in combination with 10-hydroxyestragole. Cells were pre-treated with the indi
and &indicate significant difference. B. Chromatograms of N2-(trans-isoestragol-30-yl)-
treated for 24 h with vehicle or 10-hydroxyestragole. All results are typical of at least 32.7. Estragole metabolism in cultured cells
Estragole metabolism was examined by incubating cells with
1 mM estragole in HEPES/HBSS (0.14 M NaCl, 5.4 mM KCl, 0.34 mM
Na2HPO4 12H2O, 0.44 mM KH2PO4, 5.6 mM glucose, 6 mM HEPES,
4 mM NaHCO3 and 1 mM CaCl2) for the indicated time points.
Estragole and its metabolites were then analysed by HPLC with UV
detection essentially as previously described (Punt et al., 2008). In
brief, separation was carried out using a Hypersil ODS C18, 5 mm13/H cells. A. DNA damage in B-13/H cells treated with cytochrome P450 and SULT
cated inhibitors for 6 h prior to addition of vehicle or 1 mM 10-hydroxyestragole. *, $
20-deoxyguanosine DNA-related adduct measurement from lysates of B-13/H cells
 separate experiments.
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mobile phase (flow rate 1 ml/min) constituting H2O (buffer A) and
acetonitrile (buffer B) with buffer B constituting 0–100% over
20 min. Eluted analytes were monitored at 225 nm between 0 and
30 min, with authentic estragole and 10-hydroxyestragole used to
confirm the identity of their peaks in chromagrams. Standard curve
and sample quantification was based on peak area using
LCSolution software (Shimadzu).
2.8. Hydroxycoumarin glucuronidation and sulphation assay
For the S9 incubations, 40 mg of human S9 extract was
incubated with 25 mM 7-hydroxycoumarin and 0.1 mM PAPS in
0.1 M Tris pH 7.4 in a total reaction volume of 100 ml. After a 10 min
incubation at 37 C, reactions were terminated by addition of 25 ml
of ice-cooled acetonitrile. Samples were then centrifuged at
16,000  g for 5 min and the supernatant retained for analysis.
Cellular activity was determined by incubating cells in 25 mM 7-
hydroxycoumarin in HEPES/HBSS for the indicated time points.
Glucuronidated, sulphated and parent 7 hydroxycoumarinFig. 3. Metabolism of estragole to 10-hydroxyestragole by B-13 and B-13/H cells. A, H
hydroxyestragole were subjected to HPLC to determine the retention time of their peaks, a
4 h. Media samples were taken at the indicated time points and 10-hydroxyestragole form
The average B-13/H protein content in these studies was 80 mg/well. Data are the mean an
experiments.concentrations were determined by HPLC analysis essentially as
previously described (Alhusainy et al., 2010) using a Shimadzu
system HPLC machine and by comparison to authentic standards
(obtained from Sigma Chem., Co., Poole, UK). Separation was
carried out using a Hypersil ODS C18, 5 mm (250  4.6 mm) column
(Thermo Scientific, UK) using a gradient created by Buffer A (0.1%
(v/v) aqueous acetic acid) and Buffer B (0.1% (v/v) acetic acid in
acetonitrile). Flow rate was 1 ml/min and gradient was as follows:
Buffer B was increased from 0 to 20% in 2 min, then 20–40% in
8 min, during which the analytes eluted. A subsequent 40–100%
increase in 2 min followed by returning to 0% buffer B in 1 min and
running for 6 min allowed for re-equilibration. Standards: 7-
hydroxycoumarin (7HC), 7HC-sulphate and 7HC-glucuronide
(dissolved in DMSO) were diluted in PBS to create working
standards at 10 mM and then subsequently doubly diluted to create
a standard curve. Acetonitrile was added to all standards and
samples to give a final concentration of 20% v/v (i.e. 100 ml
sample + 25 ml acetonitrile), prior to centrifugation at 20,000  g
for 5 min and injection (20 ml). Eluted analytes were monitored at
280 nm between 2 and 10 min. Standard curve and samplePLC separation of estragole and 10-hydroxyestragole. Authentic estragole and 10-
nd are indicated. B. Production of 10-hydroxyestragole by B-13 and B-13/H cells over
ation determined by HPLC. Results were normalised to cell protein concentration.
d standard deviation of 3 replicates from the same experiment, typical of 3 separate
Fig. 4. B-13 and B-13/H cells express SULT transcripts and SULT2B protein. A. RT-PCR of indicated transcripts in B-13 and B-13/H cells and rat liver. DNA samples from the qRT-
PCR runs of B were separated and visualised by agarose gel electrophoresis. B. qRT-PCR of indicated transcripts in B-13 and B-13/H cells and rat liver. Expression of transcripts
was normalised to 18S rRNA expression and expressed relative to rat liver. *Significantly different level of expression between B-13 and B-13/H cells; $ Significantly different
level of expression between rat hepatocytes and both B-13 and B-13/H cells C. RT-PCR for SULT2B1a and SULT2B1b mRNA transcripts in indicated samples. D. Western blot for
indicated proteins in B-13 and B-13/H cells and rat liver. Results are typical of at least 3 separate determinations.
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P.M. Probert et al. / Toxicology Letters 243 (2016) 98–110 105quantification was based on peak area using LCSolution software
(Shimadzu). Conjugation rates were normalised to protein
concentation as determined by the Lowry assay.
2.9. SULT assay
Cell sample extracts were prepared in 5 mM phosphate buffer
(pH 6.5) supplemented with 10 mM dithiothreitol. Human liver
was obtained via the Newcastle Hepatopancreatobiliary Research
Tissue Bank with full ethical approval and donor consent.
S9 extract (from donor NHL47) was prepared by homogenising
washed liver tissue in ice cold TKMS buffer (50 mM Tris; 25 mM
KCl, 5 mM MgCl2 and 250 mM sucrose—pH 7.5.) using a dounce
homogeniser, filtering through bolting cloth and centrifugation at
12,000  g for 20 min at 4 C. The supernatant (S9) was retained
and used for subsequent experiments. To determine SULT activities
using a variety of substrates, a reaction cocktail was prepared
consisting of 50 mM phosphate buffer (pH 6.5), 24 mM dithio-
threitol, 5 mM MgCl2 and 1.28 mM [35S]-PAPS (PerkinElmer, Seer
Green, UK). 50ul pf the reaction cocktail was added to cell or S9
extracts in 100ml 5 mM KH2PO4 and 10 mM dithiothreitol (pH 6.5)
with substrates or inhibitors as required and incubated for 30 min
at 37 C. Reactions were stopped through the addition of 100ml of a
1:1 (v:v) solution of 100 mM barium hydroxide and 100 mM
barium acetate. Free PAPS was precipitated by addition of 50ml of
100 mM zinc sulphate, centrifugation at 16,000  g for 3 min,
addition of 50 ml of 100 mM barium hydroxide and 50 ml of
100 mM zinc sulphate and centrifugation at 16,000  g for 3 min.
300 ml of the supernatant was transferred to 5 ml of scintillant
(Optiphase HiSafe 3, PerkinElmer) and 35S product radioactivity
determined using a Tri-Carb 2700TR scintillation counter.
2.10. Immunohistochemistry
Liver was formalin-fixed and processed for immunohistochem-
istry essentially as previously outlined (Probert et al., 2014b). The
same primary antibodies used for Western blotting were used for
immunohistochemistry. For SULT2B1, after antigen retrieval and
before serum blocking, tissues were blocked with avidin, then
biotin, for 20 min respectively (Vector Laboratories, Peterborough,
UK). The secondary antibody used was biotinylated anti-goat
(Sigma) and following secondary antibody incubation and washing
tissues were incubated with Vectorstain ABC reagent (Vector
Laboratories) for 30 min prior to detection of antibody binding.
2.11. Statistics
Significance was tested with by the Student’s unpaired t-test
(for testing between 2 groups) or by ANOVA followed by the
Bonferroni–Holm post hoc test (for testing multiple groups).
Significance was achieved where p < 0.05.
3. Results
3.1. 10-hydroxyestragole genotoxicity in B-13/H cells is inhibited by
general SULT inhibitors
Exposing B-13 or B-13/H cells to estragole at concentrations up
to 1 mM did not result in a detectable increase in DNA damage as
determined by comet assays. In contrast, exposing B-13/H cells to
10-hydroxyestragole resulted in a dose-dependent increase in DNA
damage at concentrations greater than 100 mM, whereas B-13 cells
where unaffected (Fig. 1B–D). Pre-treating B-13/H cells with
cytochrome P450 inhibitors ketoconazole or SKF525a lead to a
trend of increased DNA damage whereas pre-treatment withgeneral SULT inhibitors quercetin (De Santi et al., 2002), r-nitro-
phenol (Eaton et al., 1996) or pentachlorophenol (Seah and Wong,
1994) significantly reduced DNA damage caused by 10-hydrox-
yestragole (Fig. 2A). Fig. 2B indicates that exposing B-13/H cells to
10-hydroxyestragole resulted in detectable levels of the predicted
E-30-N2-dGuo DNA adduct associated with sulphation activation of
estragole. There was no evidence of adduct formation with high
1 mM concentrations of estragole (data not shown). Examining the
metabolism of estragole demonstrated that B-13/H cells were
more active than B-13 cells in generating 10 hydroxyestragole
(Fig. 3). However, the levels of 10-hydroxyestragole did not exceed
at its maximum (at 2 h) approximately 26 mM in the medium of B-
13/H cultures (Fig. 3B).
These data suggest that B-13/H cells do not convert estragole
to 10-hydroxyestragole sufficiently to give rise to detectable levels
of DNA damage but are capable of conjugating 10-hydroxyestra-
gole with sulphate catalysed by a SULT enzyme(s) leading to the
production of 10-sulphoxyestragole, its reactive carbocation and
genotoxicity.
3.2. B-13/H cells do not express functionally significant levels of
SULT1A1
A previous RT-PCR study indicated that a variety of genes
defined as encoding phase II enzymes (SULTs UDPGTs and GSTs) are
expressed in B-13/H cells at the level of mRNA (Probert et al.,
2014a). To determine the levels of expression of SULTs relative to
normal rat liver, quantitative expression levels of SULTs and PAPSSs
identified as being expressed in B-13/H cells were examined
quantitatively at the level of mRNA and protein in B-13 cells, B-13/
H cells, male rat liver and male rat pancreas [note, that B-13 cells
have been shown to be derived from male rats (Fairhall et al.,
2013)].
Fig. 4A demonstrates that the quantitative RT-PCR conditions
amplified a single amplicon of the correct size for each transcript.
For all SULT transcripts, there was an induction in the expression of
mRNAs when B-13 cells were differentiated into B-13/H cells,
except for SULT4A1 which remained unaffected (Fig. 4B). In
comparison to rat liver however, expression of SULT1A1 and
SULT1B1 mRNAs were between 10 and 100 fold lower than the
levels expressed in rat liver (Fig. 4B). In contrast, both B-13 and B-
13/H cells expressed SULT2B1 and SULT4A1 mRNAs between 10
and 100 fold higher than the levels expressed in rat liver (Fig. 4B).
The SULT2B1 gene produces two transcripts, SULT2B1a and
SULT2B1b (and both transcripts are predicted to be amplified by
the primer pair used in qRT-PCR). Fig. 4C indicates the
SULT2B1 mRNA expression is likely composed entirely of
SULT2B1b transcripts, since only the SULT2B1b transcript was
detectable by RT-PCR using variant-specific primers (see Supple-
mentary Fig. 1). Fig. 4B indicates that PAPSS1 mRNA transcripts
where expressed similarly in both B-13 and B-13/H cells at greater
than 10 fold the levels detected in rat liver whereas PAPSS2 mRNA
levels were greater than 10 fold lower. Western blotting
confirmed that both SULT2B1 and SULT4A1 proteins were readily
detectable in B-13 and B-13/H cells (Fig. 4D).
These data indicate that both B-13 and B-13/H cells express a
restricted set of SULT and PAPSS proteins and therefore suggest a
potential capacity for sulphation of a limited set of substrates.
However, the expression pattern of these genes in B-13/H cells is
not reflective of the pattern observed in male rat hepatocytes and
notably, SULT1A1–determined to be the major isoform mediating
the conjugation of 10-hydroxyestragole that leads to the genera-
tion of a genotoxic carbocation (Herrmann et al., 2012) – was
expressed at very low to undetectable levels in B-13 and B-13/H
cells.
Fig. 5. B-13/H but not B-13 cells show SULT2B enzyme activity. A. HPLC separation of 7-HC, 7-HC- glucuronide and 7-HC- sulphate. B. HPLC separation of S9 7-HC incubation
and 7-HC standards. C. Metabolism of 7-HC by B-13 and B-13/H cells over 4 h. Media samples were taken at the indicated time points and 7-HC-sulphate and 7-HC-
glucuronide formation determined by HPLC. Results were normalised to cell protein concentration. D. 35S PAPS utilisation in B-13/H cell lysates following addition of the
indicated substrates. Results were normalised to protein concentration E. 35S PAPS utilisation in human liver S9 and B-13/H cell lysate incubated with 4-MU alone or in
combination with PCP. *indicates significant difference. All results are typical of at least 3 separate experiments.
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13 or B-13/H cells
7 Hydroxycoumarin is primarily sulphated by SULT1A1 as well
as being a substrate for UDP-glucuronyl transferases (UDP-GTs). To
confirm that B-13 and B-13/H cells express low levels of SULT1A1,
cells were incubated with 7 hydroxycoumarin and medium
analysed for the presence of glucuronidated and sulphated
conjugates. Fig. 5A–C show that 7 hydroxycoumarin glucuronide
was readily generated in both B-13 and B-13/H cells whereas the
sulphated conjugate was not detected despite greater than 60%
disappearance of 7 hydroxycoumarin during the time course of
incubations. This disappearance and appearance of glucuronide
conjugate demonstrates that the absence of a sulphated conjugate
was not associated with a lack of cellular uptake.
In contrast, sulphation of SULT2B1 substrates-DHEA, pregnen-
olone and 4MU was detected in B-13/H extracts, in addition to
estragole (which was hydroxylated in the extract, data not shown)Fig. 6. Rat and human cholangiocytes express SULT2B1. Photomicrographs of rat and
3 separate rat and human liver samples. Human liver sample shown is from donor NH
inhibited by co-incubation with antigen blocking peptide sequence (see Supplementarand 10-hydroxyestragole (Fig. 5D). Despite similar expression of
SULT mRNA transcripts and proteins in B-13 and B-13/H cells,
functional activity towards all these substrates in B-13 cells was
not observed (data not shown).
Fig. 5E demonstrates that in comparison to human liver
S9 extract, total sulphation of 4MU in B-13/H cell extracts remains
around 10% of the levels observed in liver extracts. However,
sulphation is inhibited by the broad spectrum SULT inhibitor
pentachlorophenol (PCP) in both S9 and B-13/H extracts,
confirming that B-13/H cells express functional SULT2B1 activity.
3.4. Cholangiocytes express SULT2B1, suggesting cholangiocytes are a
potential target for estragole genotoxicity
Since the most common tumour observed in male rats exposed
to estragole was multiple cholangiocarcinomas (Miller et al., 1983;
Bristol, 2011), we hypothesised that SULT expression in chol-
angiocytes may play a role in this process. Immunohistochemical human liver immunostained for SULT2B1. Results are representative of at least
L17. Arrows indicate bile ducts lined with cholangiocytes. Immunoreactivity was
y Fig. 4).
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restricted to hepatocytes, with the highest levels present in
hepatocytes in the centrilobular region of the lobule in rat liver.
SULT1A1 expression was also high in human hepatocytes although
expression was patchy throughout the lobule, expression appeared
distinct from rat in that levels were high in hepatocytes in the
centrilobular and periportal regions of the lobule (Supplementary
Fig. 2). SULT1B1 expression in rat liver was highest in cholangio-
cytes, with some expression in the hepatocytes in the centrilobular
region around the central vein. In contrast, SULT1B1 expression in
human liver was not apparent in cholangiocytes and expression in
hepatocytes was highest in the periportal region (Supplementary
Fig. 3).
Expression of SULT2A1 in both rat and human showed a similar
panlobular expression pattern in hepatocytes. In addition,Fig. 7. Rat and human cholangiocytes express SULT2B1b mRNA transcripts. A. Photomic
analysis for the indicated transcript in rat tissues. Data are typical of determinations fro
marker cytokeratin 19 (CK-19, green) in human cholangiocyte preparations after cultu
isolations. D. RT-PCR analysis for the indicated transcript in human cells. Data are typica
references to colur in this figure legend, the reader is referred to the web version of thexpression of SULT2B1 was high in cholangiocytes in both rat
and human liver sections (Fig. 6). These data were underpinned by
the observation that addition of peptide to which the anti-
SULT2B1 antibody binds, blocked antibody binding to liver sections
indicating that stain intensity is associated with specific binding of
anti-SULT2B1 to SULT2B1 alone (Supplementary Fig. 4). Further-
more, RT-PCR analysis for transcripts from isolated rat liver biliary
tree confirmed enriched expression of the SULT2B1b transcript
(Fig. 7A–B). Isolation of a pure population of human cholangiocytes
using an antibody-bead based approach (Fig. 7C, note this
procedure is not successful when applied to rat cells) confirmed
enriched expression of the SULT2B1b transcript in human
cholangiocytes (Fig. 7D).
Western blotting (Fig. 4D) suggested that rat liver expressed
SULT4A1 proteins. However, immunohistochemical staining forrograph of remaining biliary tree after extensive digestion of liver tissue. B. RT-PCR
m at least 3 separate tissue donors. C. Immunocytochemical analysis for the ductal
re of cells for 24 h. Nuclei are stained with DAPI (blue). Data typical of 6 separate
l of determinations from at least 3 separate tissue donors. (For interpretation of the
is article.)
P.M. Probert et al. / Toxicology Letters 243 (2016) 98–110 109SULT4A1 expression was unsuccessful on both rat and human liver
sections (data not shown), suggesting the antigen(s) recognised by
the anti-SULT4A1 antibody was destroyed by tissue fixation and/or
processing.
4. Discussion
The initial aim of this work was to determine whether the B-13/
H cell platform was able to metabolise a phase II enzyme-activated
genotoxin (estragole) and therefore provide a simple in vitro
genotoxicity screening system. The data demonstrate that there
was little evidence for genotoxicity when cells were exposed to
estragole, likely because estragole is extensively metabolised to
non-genotoxic metabolites as previously reported (Anthony et al.,
1987; Luo and Guenthner, 1994; Luo and Guenthner, 1995; Punt
et al., 2008); B-13/H cells express high levels of a number of
cytochrome P450s (Marek et al., 2003; Probert et al., 2014a) and as
reported herein, the concentrations of 10-hydroxyestragole gener-
ated from estragole were low. However, addition of the proximate
SULT1A1-activated genotoxic metabolite 10-hydroxyestragole to B-
13/H cells resulted in a clear dose-dependent increase in DNA
damage in comet assays, confirmed by detection of E-30-N2-dGuo
adducts. DNA damage was inhibited by general SULT inhibitors,
supporting a role for SULTS in the activation of 10-hydroxyestragole
in B-13/H cells. Addition of general cytochrome P450 inhibitors
had a tendency to increase the genotoxicity of 10-hydroxyestragole
suggesting that cytochrome P450s also metabolise 10-hydroxyes-
tragole to non-genotoxic metabolites in B-13/H cells.
Although B-13/H cells are a good model for rat hepatocytes in
terms of cytochrome P450 expression, B-13/H cells did not express
significant levels of the SULT1A1 as determined by qRT-PCR,
Western blotting and 7 hydroxycoumarin conjugation with
sulphate. In this respect therefore, B-13/H cells appear functionally
null for SULT1A1. Since B-13/H cells were able to sulphate 10-
hydroxyestragole in cell extracts, these observations suggest that
10-hydroxyestragole was conjugated by other SULTs.
Progenitor cells in the liver are bi-potential, forming both
hepatocytes and cholangiocytes. Although the B-13 progenitor cell
is thought to derive from the embryologically closely-related
pancreas (Probert et al., 2015), recent work has identified that the
B-13 cell can express some cholangiocyte markers (Al-Adsani et al.,
2010). The B-13/H cells may therefore be more reflective of rat
cholangiocytes – rather than hepatocyte – in terms of SULTs
expression.
Physiologically-based biokinetic modeling of estragole metab-
olism in the rat suggests that at low doses of estragole, there is
primarily detoxication through formation of 4-allylphenol, occur-
ring mainly in the lung and kidney. Saturation of this metabolic
pathway leads to increased formation of the proximate carcino-
genic metabolite 10-hydroxyestragole in the liver and to a relative
increase in formation of 10-hydroxyestragole glucuronide and 10-
sulphooxyestragole, the latter being the ultimate carcinogenic
metabolite of estragole (Punt et al., 2008). 10-hydroxyestragole has
been shown to be metabolised almost exclusively to 10-sulphoox-
yestragole by SULT1A1 in man (Herrmann et al., 2012). The data in
this paper suggests that in rat, other SULTs such as SULT2B1b, may
be capable of activating 10-hydroxyestragole. This paper also
demonstrates that rat and human cholangiocytes express SULT2B1,
but not SULT1A1. Since the most common tumour observed in
male rats exposed to estragole was multiple cholangiocarcinomas
(Miller et al., 1983; Bristol, 2011), the genotoxic metabolic pathway
in rats may be significantly dependent on activation by SULT2B1. It
is of interest to note that for the related alkenylbenzene
methyleugenol, human SULT2B1b did not seem to be involved
in its bioactivation (Herrmann et al., 2012). This suggests that
depending on the alkenylbenzene, species or tissue under study,the SULT enzymes involved in bioactivation of the alkenylbenzenes
may vary. This could imply that the relevance of the cholangio-
carcinomas observed in estragole-exposed rats may need to be
reconsidered for human risk assessment.
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